BRCA1, BRCA2, PALB2, and CDKN2A mutations in familial pancreatic cancer: A PACGENE study

Genetics in Medicine

Volumn 17, Issue 7, 2015, Pages 569-577

  Zhen, David B ^a   Rabe, Kari G ^a   Gallinger, Steven ^b   Syngal, Sapna ^c   Schwartz, Ann G ^d   Goggins, Michael G ^e   Hruban, Ralph H ^e   Cote, Michele L ^d   McWilliams, Robert R ^a   Roberts, Nicholas J ^e,f   Cannon Albright, Lisa A ^g   Li, Donghui ^h   Moyes, Kelsey ⁱ   Wenstrup, Richard J ⁱ   Hartman, Anne Renee ⁱ   Seminara, Daniela ^j   Klein, Alison P ^e   Petersen, Gloria M ^a  

^a MAYO CLINIC   (United States)

^b UNIVERSITY OF TORONTO   (Canada)

^c BRIGHAM AND WOMEN S HOSPITAL   (United States)

^d WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^f JOHNS HOPKINS UNIVERSITY   (United States)

^g UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

^h UNIVERSITY OF TEXAS   (United States)

ⁱ Myriad Genetic Laboratories   (United States)

^j NATIONAL CANCER INSTITUTE   (United States)

more..

Author keywords

BRCA1; BRCA2; CDKN2A; familial pancreatic cancer; PALB2

Indexed keywords

BRCA1 PROTEIN; BRCA2 PROTEIN; CYCLIN DEPENDENT KINASE INHIBITOR 2A; DNA; PALB2 PROTEIN; PROTEIN; UNCLASSIFIED DRUG; BRAP PROTEIN, HUMAN; BRCA2 PROTEIN, HUMAN; NUCLEAR PROTEIN; PALB2 PROTEIN, HUMAN; TUMOR SUPPRESSOR PROTEIN; UBIQUITIN PROTEIN LIGASE;

ADULT; AGED; ARTICLE; BREAST CANCER; CANCER RISK; CARCINOGENESIS; COMPARATIVE STUDY; CONTROLLED STUDY; DNA DETERMINATION; FAMILIAL CANCER; FAMILY HISTORY; FEMALE; FIRST DEGREE RELATIVE; GENE DELETION; GENE REARRANGEMENT; GENE SEQUENCE; GENETIC RISK; GENETIC SCREENING; GENETIC VARIABILITY; GERMLINE MUTATION; HUMAN; MAJOR CLINICAL STUDY; MALE; MELANOMA; MOLECULAR PATHOLOGY; MUTATIONAL ANALYSIS; OVARY CANCER; PANCREAS CANCER; PREVALENCE; RISK ASSESSMENT; SINGLE NUCLEOTIDE POLYMORPHISM; CARCINOMA; GENETIC PREDISPOSITION; GENETICS; MIDDLE AGED; PANCREAS TUMOR; TUMOR SUPPRESSOR GENE; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; BRCA2 PROTEIN; CARCINOMA; CYCLIN-DEPENDENT KINASE INHIBITOR P16; FEMALE; GENES, BRCA1; GENES, BRCA2; GENES, P16; GENETIC PREDISPOSITION TO DISEASE; GERM-LINE MUTATION; HUMANS; MALE; MIDDLE AGED; NUCLEAR PROTEINS; PANCREATIC NEOPLASMS; TUMOR SUPPRESSOR PROTEINS; UBIQUITIN-PROTEIN LIGASES;

EID: 84942550897     PISSN: 10983600     EISSN: 15300366     Source Type: Journal    
DOI: 10.1038/gim.2014.153     Document Type: Article

References (40)

1. Howlader N, Noone AM, Krapcho M, et al. SEER Cancer Statistics, 1975-2011. National Cancer Institute: Bethesda, MD, 2014. http://seer. cancer. gov/csr/1975-2011/. Accessed April 2014.
2. Rahib L, Smith BD, Aizenberg R, Rosenzweig AB, Fleshman JM, Matrisian LM. Projecting cancer incidence and deaths to 2030: the unexpected burden of thyroid, liver, and pancreas cancers in the United States. Cancer Res 2014;74:2913-2921.
3. Canto MI, Harinck F, Hruban RH, et al.; International Cancer of Pancreas Screening (CAPS) Consortium. International Cancer of the Pancreas Screening (CAPS) Consortium summit on the management of patients with increased risk for familial pancreatic cancer. Gut 2013;62:339-347.
4. Klein AP. Identifying people at a high risk of developing pancreatic cancer. Nat Rev Cancer 2013;13:66-74.
5. Klein AP. Genetic susceptibility to pancreatic cancer. Mol Carcinog 2012;51:14-24.
6. Thompson D, Easton DF; Breast Cancer Linkage Consortium. Cancer Incidence in BRCA1 mutation carriers. J Natl Cancer Inst 2002;94:1358-1365.
7. Breast Cancer Linkage Consortium. Cancer risks in BRCA2 mutation carriers. J Natl Cancer Inst 1999;91:1310-1316.
8. Lynch HT, Deters CA, Snyder CL, et al. BRCA1 and pancreatic cancer: pedigree findings and their causal relationships. Cancer Genet Cytogenet 2005;158:119-125.
9. Iqbal J, Ragone A, Lubinski J, et al.; Hereditary Breast Cancer Study Group. The incidence of pancreatic cancer in BRCA1 and BRCA2 mutation carriers. Br J Cancer 2012;107:2005-2009.
10. Lucas AL, Frado LE, Hwang C, et al. BRCA1 and BRCA2 germline mutations are frequently demonstrated in both high-risk pancreatic cancer screening and pancreatic cancer cohorts. Cancer 2014;120:1960-1967.
11. Al-Sukhni W, Rothenmund H, Borgida AE, et al. Germline BRCA1 mutations predispose to pancreatic adenocarcinoma. Hum Genet 2008;124:271-278.
12. Lal G, Liu G, Schmocker B, et al. Inherited predisposition to pancreatic adenocarcinoma: role of family history and germ-line p16, BRCA1, and BRCA2 mutations. Cancer Res 2000;60:409-416.
13. Axilbund JE, Argani P, Kamiyama M, et al. Absence of germline BRCA1 mutations in familial pancreatic cancer patients. Cancer Biol Ther 2009;8:131-135.
14. Murphy KM, Brune KA, Griffin C, et al. Evaluation of candidate genes MAP2K4, MADH4, ACVR1B, and BRCA2 in familial pancreatic cancer: deleterious BRCA2 mutations in 17%. Cancer Res 2002;62:3789-3793.
15. Couch FJ, Johnson MR, Rabe KG, et al. The prevalence of BRCA2 mutations in familial pancreatic cancer. Cancer Epidemiol Biomarkers Prev 2007;16:342-346.
16. Stadler ZK, Salo-Mullen E, Patil SM, et al. Prevalence of BRCA1 and BRCA2 mutations in Ashkenazi Jewish families with breast and pancreatic cancer. Cancer 2012;118:493-499.
17. Lucas AL, Shakya R, Lipsyc MD, et al. High prevalence of BRCA1 and BRCA2 germline mutations with loss of heterozygosity in a series of resected pancreatic adenocarcinoma and other neoplastic lesions. Clin Cancer Res 2013;19:3396-3403.
18. Drew Y, Mulligan EA, Vong WT, et al. Therapeutic potential of poly(ADP-ribose) polymerase inhibitor AG014699 in human cancers with mutated or methylated BRCA1 or BRCA2. J Natl Cancer Inst 2011;103:334-346.
19. Lowery MA, Kelsen DP, Stadler ZK, et al. An emerging entity: pancreatic adenocarcinoma associated with a known BRCA mutation: clinical descriptors, treatment implications, and future directions. Oncologist 2011;16:1397-1402.
20. Xia B, Sheng Q, Nakanishi K, et al. Control of BRCA2 cellular and clinical functions by a nuclear partner, PALB2. Mol Cell 2006;22:719-729.
21. Xia B, Dorsman JC, Ameziane N, et al. Fanconi anemia is associated with a defect in the BRCA2 partner PALB2. Nat Genet 2007;39:159-161.
22. Jones S, Hruban RH, Kamiyama M, et al. Exomic sequencing identifies PALB2 as a pancreatic cancer susceptibility gene. Science 2009;324:217.
23. Slater EP, Langer P, Niemczyk E, et al. PALB2 mutations in European familial pancreatic cancer families. Clin Genet 2010;78:490-494.
24. Harinck F, Kluijt I, van Mil SE, et al. Routine testing for PALB2 mutations in familial pancreatic cancer families and breast cancer families with pancreatic cancer is not indicated. Eur J Hum Genet 2012;20:577-579.
25. Grant RC, Al-Sukhni W, Borgida AE, et al. Exome sequencing identifies nonsegregating nonsense ATM and PALB2 variants in familial pancreatic cancer. Hum Genomics 2013;7:11.
26. Goldstein AM, Fraser MC, Struewing JP, et al. Increased risk of pancreatic cancer in melanoma-prone kindreds with p16INK4 mutations. N Engl J Med 1995;333:970-974.
27. Bartsch DK, Sina-Frey M, Lang S, et al. CDKN2A germline mutations in familial pancreatic cancer. Ann Surg 2002;236:730-737.
28. Harinck F, Kluijt I, van der Stoep N, et al. Indication for CDKN2A-mutation analysis in familial pancreatic cancer families without melanomas. J Med Genet 2012;49:362-365.
29. McWilliams RR, Wieben ED, Rabe KG, et al. Prevalence of CDKN2A mutations in pancreatic cancer patients: implications for genetic counseling. Eur J Hum Genet 2011;19:472-478.
30. Petersen GM, de Andrade M, Goggins M, et al. Pancreatic cancer genetic epidemiology consortium. Cancer Epidemiol Biomarkers Prev 2006;15:704-710.
31. Frank TS, Deffenbaugh AM, Reid JE, et al. Clinical characteristics of individuals with germline mutations in BRCA1 and BRCA2: analysis of 10,000 individuals. J Clin Oncol 2002;20:1480-1490.
32. Hendrickson BC, Judkins T, Ward BD, et al. Prevalence of five previously reported and recurrent BRCA1 genetic rearrangement mutations in 20,000 patients from hereditary breast/ovarian cancer families. Genes Chromosomes Cancer 2005;43:309-313.
33. Judkins T, Rosenthal E, Arnell C, et al. Clinical significance of large rearrangements in BRCA1 and BRCA2. Cancer 2012;118:5210-5216.
34. Richards CS, Bale S, Bellissimo DB, et al. ACMG recommendations for standards for interpretation and reporting of sequence variations: revisions 2007. Genet Med 2008;10:294-300.
35. McWilliams RR, Bamlet WR, de Andrade M, et al. Polymorphic variants in hereditary pancreatic cancer genes are not associated with pancreatic cancer risk. Cancer Epidemiol Biomarkers Prev 2009;18:2549-2552.
36. Klein AP, Brune KA, Petersen GM, et al. Prospective risk of pancreatic cancer in familial pancreatic cancer kindreds. Cancer Res 2004;64:2634-2638.
37. Langer P, Kann PH, Fendrich V, et al. Five years of prospective screening of high-risk individuals from families with familial pancreatic cancer. Gut 2009;58:1410-1418.
38. Verna EC, Hwang C, Stevens PD, et al. Pancreatic cancer screening in a prospective cohort of high-risk patients: a comprehensive strategy of imaging and genetics. Clin Cancer Res 2010;16:5028-5037.
39. Goggins M, Schutte M, Lu J, et al. Germline BRCA2 gene mutations in patients with apparently sporadic pancreatic carcinomas. Cancer Res 1996;56: 5360-5364.
40. Lennon AM, Wolfgang CL, Canto MI, et al. The early detection of pancreatic cancer: what will it take to diagnose and treat curable pancreatic neoplasia Cancer Res 2014;74:3381-3389.